Matthias Guckenberger/X
May 21, 2025, 01:21
Matthias Guckenberger: Multimodality treatment in synchronous oligometastatic NSCLC
Matthias Guckenberger, Chairman at UniversitätsSpital Zürich, shared a post on LinkedIn:
“Hot off the press
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial.
Background:
Several studies reported improved PFS and OS by adding metastases-directed therapy to SoC systemic therapy for patients with oligometastatic NSCLC
The efficacy and safety of such a combined modality treatment strategy is unknown in non-driver mutated NSCLC treated with modern immune checkpoint inhibition (ICI) and chemotherapy
Objective:
To test the hypothesis whether an induction treatment of concurrent ICI, chemotherapy and SBRT to all oligometastases followed by surgery or definitive radiotherapy of the primary tumour improves PFS as compared to historical resultsMethods:
Prospective, international, multicentre, single-arm, phase II trial
Enrollment of synchronous non-driver mutated, oligometastatic NSCLC
Treatment: Induction carboplatin plus paclitaxel, durvalumab and metastasis-directed SBRT, followed by definitive radiotherapy or surgery of the primary tumour (if no disease progression at the 3-month restaging) followed by maintenance durvalumab for maximum one year
Primary endpoint: PFS improvement from 25% to 50% at 1 year
Results:
Enrollment of 49 patients from 11/2019 to 07/2022
47 patients started treatment, 10 progressed and 2 died before restaging, 35 proceeded to definitive therapy of the locoregional primary (11 surgery, 24 radiotherapy)
Among the first 42 evaluable patients: 14 (33%; ≥17 required) reached one year without progression, and the null hypothesis could not be rejected
One-year overall survival rate for all patients: 74.9%
Treatment-related grade ≥ 3 adverse events: 34% of patients; no grade 5 event
Conclusions:
The CHESS trial did not meet its primary endpoint.
However, the favourable safety profile and promising overall survival provided the basis for further intensification of induction systemic therapy (addition of tremelimumab in a subsequent study cohort; CHESS–Cohort 2)
Thanks to all collaborators, investigators, and especially all patients and their families
Thanks to ETOP IBCSG Partners Foundation and SAKK Swiss Group for Clinical Cancer Research for making this trial possible.”
Title: Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial
Authors: Matthias Guckenberger, Isabelle Opitz, Tereza Dellaporta, Alessandra Curioni-Fontecedro, Thomas Frauenfelder, Karin Ribi, Ferdinando Cerciello, Ivana Sullivan, Lizza Hendriks, Miriam Dorta, Ana Callejo, Joachim Aerts, Alfredo Addeo, Anne-Marie C. Dingemans, Giulia Pasello, Mariano Provencio, Filippo de Marinis, Nuria Mederos-Alfonso, Heidi Roschitzki-Voser, Barbara Ruepp, Rolf Stahel
Read the Full Article.
More posts featuring Matthias Guckenberger.
Alessandra Curioni Fontecedro
Alfredo Addeo
Ana Callejo
Anne-Marie C. Dingemans
Barbara Ruepp
cancer
Cancer research
Ferdinando Cerciello
Filippo de Marinis
Giulia Pasello
Heidi Roschitzki-Voser
Isabelle Opitz
Ivana Sullivan
Joachim Aerts
Karin Ribi
Lizza Hendriks
Mariano Provencio
Matthias Guckenberger
Miriam Dorta
NSCLC
Nuria Mederos-Alfonso
OncoDaily
Oncology
Rolf Stahel
Tereza Dellaporta
Thomas Frauenfelder
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 22, 2025, 17:32
May 22, 2025, 17:25
May 22, 2025, 16:22
May 22, 2025, 15:55